JiangSu WuZhong Pharmaceutical Development Balance Sheet Health
Financial Health criteria checks 4/6
JiangSu WuZhong Pharmaceutical Development has a total shareholder equity of CN¥1.8B and total debt of CN¥1.8B, which brings its debt-to-equity ratio to 101.8%. Its total assets and total liabilities are CN¥4.4B and CN¥2.7B respectively.
Key information
101.8%
Debt to equity ratio
CN¥1.80b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.66b |
| Equity | CN¥1.77b |
| Total liabilities | CN¥2.65b |
| Total assets | CN¥4.42b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 600200's short term assets (CN¥3.0B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 600200's short term assets (CN¥3.0B) exceed its long term liabilities (CN¥290.1M).
Debt to Equity History and Analysis
Debt Level: 600200's net debt to equity ratio (8.1%) is considered satisfactory.
Reducing Debt: 600200's debt to equity ratio has increased from 48.4% to 101.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 600200 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 600200 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.